Advertisement

Sports Medicine

, Volume 46, Issue 5, pp 611–617 | Cite as

Considerations in the Use of Stimulants in Sport

  • Claudia L. ReardonEmail author
  • Robert M. Factor
Current Opinion

Abstract

Medication treatment of adult athletes with attention-deficit/hyperactivity disorder (ADHD) is controversial. Some articles and guidelines support the use of stimulant medications in this population, while others advise against it. We believe that the important issues regarding the use of stimulant medications in athletes include the likelihood of performance enhancement, poor inter-rater reliability of ADHD diagnosis in relation to therapeutic use, policies of sport-governing bodies, psychiatric treatment of mental illness, and dangerous consequences of use. We review the literature on these five issues and conclude by discussing the ethical principle of fairness, and suggest some proposals regarding the use of stimulants by athletes that balance these five issues and fairness. Our ultimate recommendation is that stimulants should not be used by high-level adult athletes.

Keywords

ADHD Symptom Atomoxetine Stimulant Medication International Olympic Committee National Collegiate Athletic Association 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

The authors report no funding for the preparation of this review and no relevant conflicts of interest. We thank Professor Russ Shafer-Landau of the University of Wisconsin-Madison Department of Philosophy (now at the University of North Carolina, Chapel Hill, CA, USA) for helpful conversations regarding the ethical issues we discussed.

References

  1. 1.
    Santosh PJ, Sattar S, Canagaratnam M. Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults. CNS Drugs. 2011;25(9):737–63.CrossRefPubMedGoogle Scholar
  2. 2.
    Parr JW. Attention-deficit hyperactivity disorder and the athlete: new advances and understanding. Clin Sports Med. 2011;30:591–610.CrossRefPubMedGoogle Scholar
  3. 3.
    Putukian M, Kreher JB, Coppel DB, et al. Attention deficit hyperactivity disorder and the athlete: an American Medical Society for Sports Medicine position statement. Clin J Sports Med. 2011;21(5):392–401.CrossRefGoogle Scholar
  4. 4.
    Corrigan B. Attention deficit hyperactivity disorder in sport: a review. Int J Sports Med. 2003;24:535–40.CrossRefPubMedGoogle Scholar
  5. 5.
    Kutcher JS. Treatment of attention-deficit hyperactivity disorder in athletes. Curr Sports Med Reports. 2011;10(1):32–6.CrossRefGoogle Scholar
  6. 6.
    NCAA guidelines to document ADHD treatment with banned stimulant medications. Addendum to the January 2009 guidelines. 20 July 2010 [online] (with a login and password). http://www.ncaa.org/drugtesting. Assessed 12 May 2012.
  7. 7.
    Shaikin B. Baseball’s 2008 drug test results released in report. Los Angeles Times, 10 January 2009 [online]. http://articles.latimes.com/2009/jan/10/sports/sp-newswire10. Accessed 17 Sept 2010.
  8. 8.
    Smith GM, Beecher HK. Amphetamine sulfate and athletic performance. I: objective effects. JAMA. 1959;170:542–7.CrossRefGoogle Scholar
  9. 9.
    Reardon CL, Factor RM. Sport psychiatry: a systematic review of diagnosis and medical treatment of mental illness in athletes. Sports Med. 2010;40(11):1–20.CrossRefGoogle Scholar
  10. 10.
    Chandler JV, Blair SN. The effect of amphetamines on selected physiological components related to athletic success. Med Sci Sports Exerc. 1980;12(1):65–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Hickey G, Fricker P. Attention deficit hyperactivity disorder, CNS stimulants and sport. Sports Med. 1999;27(1):11–21.CrossRefPubMedGoogle Scholar
  12. 12.
    Conant-Norville DO, Tofler IR. Attention deficit/hyperactivity disorder and psychopharmacologic treatments in the athlete. Clin Sports Med. 2005;24:829–43.CrossRefPubMedGoogle Scholar
  13. 13.
    World Anti-Doping Agency medical information to support the decisions of TUECs. Attention deficit hyperactivity disorder (ADHD) in children and young adults. Version 3.0. December 2011 [online]. http://www.wada-ama.org/Documents/Science_Medicine/Medical_info_to_support_TUECs/WADA_Medical_info_ADHD_3.0_EN.pdf. Accessed 28 July 2013.
  14. 14.
    Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.Google Scholar
  15. 15.
    Sutherland SM, Adler LA, Chen C, et al. An 8-week randomized controlled trial of atomoxetine, atomoxetine plus buspirone, or placebo in adults with ADHD. J Clin Psychiatry. 2012;73(4):445–50.CrossRefPubMedGoogle Scholar
  16. 16.
    Pliszka S, Bernet W, Bukstein O, et al. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:894–921.CrossRefPubMedGoogle Scholar
  17. 17.
    Piacentini MF, Meeusen R, Buyse L, et al. No effect of a noradrenergic reuptake inhibitor on performance in trained cyclists. Med Sci Sports Exerc. 2002;34(7):1189–93.CrossRefPubMedGoogle Scholar
  18. 18.
    Kang KD, Choi JW, Kang SG, et al. Sports therapy for attention, cognitions and sociality. Int J Sports Med. 2011;32(12):953–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Choi JW, Han DH, Kang KD, et al. Aerobic exercise and attention deficit hyperactivity disorder: brain research. Med Sci Sports Exerc. 2015;47(1):33–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Gapin JI, Labban JD, Etnier JL. The effects of physical activity on attention deficit hyperactivity disorder symptoms: the evidence. Prev Med. 2011;52:570–4.CrossRefGoogle Scholar
  21. 21.
    Kamp CF, Sperlich B, Holmberg HC. Acta Paediatr. 2014;103(7):709–14.PubMedGoogle Scholar
  22. 22.
    Humphreys KL, Eng T, Lee SS. Stimulant medication and substance use outcomes: a meta-analysis. JAMA. 2013;70(7):740–9.Google Scholar
  23. 23.
    Roelands B, Hasegawa H, Watson P, et al. The effects of acute dopamine reuptake inhibition on performance. Med Sci Sports Exerc. 2008;40(5):879–85.CrossRefPubMedGoogle Scholar
  24. 24.
    Deligiannis A, Bjornstad H, Carre F, et al. ESC study group of sports cardiology position paper on adverse cardiovascular effects of doping in athletes. Eur J Cardiovasc Prev Rehabil. 2006;13(5):687–94.CrossRefPubMedGoogle Scholar
  25. 25.
    Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder. Circulation. 2008;117:2407–423.CrossRefPubMedGoogle Scholar
  26. 26.
    Wilens TE, Adler LA, Adams J, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47(1):21–31.CrossRefPubMedGoogle Scholar
  27. 27.
    Non-medical use of ADHD meds examined in Convention session. 2012 [online]. http://www.ncaa.org/wps/wcm/connect/public/NCAA/Resources/Latest+News/2012/January/Non-medical+use+of+ADHD+meds+examined+in+Convention+session. Accessed 21 July 2013.
  28. 28.
    Pelham WE, Burrows-MacLean L, Gnagy EM, et al. Transdermal methylphenidate, behavioral and combined treatment for children with ADHD. Exp Clin Psychopharmacol. 2005;13:111–26.CrossRefPubMedGoogle Scholar
  29. 29.
    Roelands B, Hasegawa H, Watson P, et al. Performance and thermoregulatory effects of chronic bupropion administration in the heat. Eur J Appl Physiol. 2009;105(3):493–8.CrossRefPubMedGoogle Scholar
  30. 30.
    World Anti-Doping Agency 2014 monitoring program. 2015 [online]. http://list.wada-ama.org/wp-content/uploads/2013/11/Monitoring-Program-2014-ENG_-FINAL.pdf. Accessed 21 Sept 2015.

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Department of PsychiatryUniversity of Wisconsin School of Medicine and Public HealthMadisonUSA

Personalised recommendations